Amicus Therapeutics (FOLD) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
November 8, 2023 7:00 AM EST3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER
Galafold® Quarterly Revenue Surpasses $100M for the First Time
Increasing FY 2023 Galafold® Revenue Growth Guidance to 16%-18% at CER
Pombiliti + Opfolda Approved and Launched in the... More
